Karo Bio acquires over 90% of MedCore

29 October 2015

Swedish drugmaker Karo Bio (STO: KARO) says it has acquired more than 90% of the shares in MedCore AB, also based in Sweden.

MedCore markets primarily licensed medtech products to pharmacies and hospitals in the Nordic region. The products target the therapeutic areas diabetes, anesthesia/intensive care and surgery. Turnover is around 50 million Swedish kronor ($5.9 million), with an operating profit expected to be slightly positive in 2015.

19 million kronor purchase price

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK